The Natural Products Association (NPA) is gearing up for its 2026 Fly-in Day, a pivotal event that underscores the organization's enduring commitment to health freedom and consumer protection. Founded in 1936, NPA has been a stalwart watchdog, advocating for the safe and compliant certification of dietary supplements while staunchly opposing government overregulation of an already regulated industry. This year's agenda is packed with critical issues, each demanding NPA's unwavering vigilance and advocacy.
Fending Off Overreach
One of the most pressing concerns on NPA's agenda is the Dietary Supplement Listings Act (S. 3677), reintroduced by outgoing Senator Richard Durbin (D-IL). If enacted, this law would mandate that supplement companies register their products, labels, proprietary blends, allergen statements, and structure/function claims with the FDA, creating a national database. While proponents argue this would enhance consumer protection by identifying bad actors, NPA vehemently disagrees. They assert that this move would introduce legal burdens, lawsuits, and compliance costs, particularly harming smaller businesses and stifling innovation.
In my opinion, the proposed law represents a significant overreach of FDA authority. It would enable the agency to control which supplements can enter or remain on the market, without scientific evidence, due process, or congressional accountability. This is a red flag for consumer freedom and innovation in the supplement industry.
Protecting Innovation
Another critical issue is the clarification of Section 201(ff)(3)(B) of the Dietary Supplement Health and Education Act (DSHEA), commonly known as the 'drug preclusion' clause. Originally designed to prevent supplement companies from bypassing the drug-approval system, this provision has been expanded by the FDA beyond Congress's original intent. The agency uses it to remove already-marketed supplement ingredients from shelves after drug companies initiate clinical research on them, creating market uncertainty and discouraging innovation.
Personally, I find this particularly fascinating. The FDA's interpretation of the clause creates an uneven playing field, prioritizing pharmaceutical interests over consumer choice and wellness. This raises a deeper question: How can we ensure that the FDA's actions align with Congress's original intent and support the innovation that drives the supplement industry?
Expanding Access
NPA is also advocating for the expansion of Health Savings Accounts (HSAs), Flexible Spending Accounts (FSAs), and Health Reimbursement Arrangements (HRAs) to cover supplements. Currently, most supplements are not automatically HSA/FSA eligible unless prescribed for a specific medical condition or accompanied by a doctor's letter of medical necessity. Expanding the Internal Revenue Code (IRC) to include a wider range of wellness and nutrition products would encourage preventive care and reduce long-term healthcare costs.
From my perspective, this is a high-impact, no-cost solution. By updating IRS publication 502, we can provide access to a broader spectrum of wellness products, promoting preventive care and potentially reducing healthcare costs. This is a win-win for consumers and the healthcare system.
Ensuring Uniformity
NPA is also rallying against the proliferation of state-level supplement initiatives, such as restrictions on supplement sales to minors or mandatory warning labels. This effort is centered around the Dietary Supplement Regulatory Uniformity Act (H.R. 7366), introduced by Congressman Nick Langworthy (R-NY) in February. The act aims to establish the FDA as the sole regulator of dietary supplements, preventing states from creating conflicting or additional requirements.
One thing that immediately stands out is the need for a common-sense approach to regulation. Governor Hochul's decision to ban the sale of over-the-counter diet pills and muscle-building supplements to minors is a prime example of how state-level restrictions can override FDA authority and hurt consumers. This raises a deeper question: How can we ensure that state-level initiatives support, rather than undermine, the FDA's regulatory framework?
Conclusion
As NPA prepares for its 2026 Fly-in Day, it is clear that the organization's mission remains as relevant as ever. By advocating for consumer protection, innovation, access, and uniformity, NPA is championing a future where health freedom is not just a right but a reality for all. In my opinion, this is a pivotal moment for the supplement industry, and NPA's efforts will shape the landscape for years to come.
